![From QSR to QMSR: Meeting FDA’s New Requirements From QSR to QMSR: Meeting FDA’s New Requirements](https://www.fdanews.com/ext/resources/Book-Covers-NEW/From-QSR-to-QMSR-500.png?height=200&t=1714569011&width=200)
Home » NICE Backs Janssen’s Stelara for Ulcerative Colitis
NICE Backs Janssen’s Stelara for Ulcerative Colitis
April 29, 2020
The UK’s National Institute for Health and Care Excellence has recommended Janssen’s Stelara (ustekinumab) for National Health Service treatment of moderate-to-severe ulcerative colitis in patients who can’t tolerate a conventional therapy or a biological agent.
NICE previously said the treatment was not cost-effective, but now says that new cost estimates for ustekinumab compared with vedolizumab are below its cost-effectiveness threshold.
NICE also noted that clinical trial data showed ustekinumab is more effective than a placebo for treating the condition.
Upcoming Events
-
21Oct